Short answer
Edgewise Therapeutics, Inc. (EWTX) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026 announced.
Edgewise Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026 announced
- Full earnings details, including financial metrics and management commentary, in Exhibit 99.1
- Results provide the latest update on Edgewise’s operating performance and financial position
Item EX-99.1 · Exhibit EX-99.1
- Cash, equivalents and marketable securities $1,743.9M, substantially strengthening funding for cardiovascular development
- Sevasemten sale generated $1.348B gain and $1.396B upfront cash, driving $1,166.2M net income versus $40.7M loss
- EDG-7500 Phase 3 HCM trial remains targeted for initiation by year-end 2026, a key clinical catalyst
- EDG-15400 Phase 2 EQUINOX-HFpEF trial dosed its first patient, expanding the cardiovascular pipeline
- R&D fell to $31.6M from $37.5M, while G&A rose to $14.6M from $9.4M as development infrastructure expanded
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Edgewise Therapeutics, Inc. 8-K filings
Get the next EWTX 8-K as it lands
Follow EWTX for push alerts, or ask the research agent what this filing means.